"Even when there are no financial constraints, if these drugs are freely available, it is very, very difficult to actually implement the programme, " said Donald de Korte, a former head of US drugs firm Merck in South Africa who is running a pilot scheme.
BBC: Africa's Aids drugs debate heats up